Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. more
Time Frame | GLTO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.04% | -2.12% | 0.77% |
1-Month Return | -19.6% | -2.54% | 2.65% |
3-Month Return | -49.64% | -6.28% | 12.3% |
6-Month Return | -58.14% | -1.36% | 13.48% |
1-Year Return | -65.94% | 9.29% | 33.47% |
3-Year Return | -91.04% | 10.05% | 32.22% |
5-Year Return | -98.5% | 43.69% | 92.85% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 111.00K | 188.00K | 441.00K | 490.00K | 830.00K | [{"date":"2019-12-31","value":13.37,"profit":true},{"date":"2020-12-31","value":22.65,"profit":true},{"date":"2021-12-31","value":53.13,"profit":true},{"date":"2022-12-31","value":59.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (111.00K) | (188.00K) | (441.00K) | (490.00K) | (830.00K) | [{"date":"2019-12-31","value":-11100000,"profit":false},{"date":"2020-12-31","value":-18800000,"profit":false},{"date":"2021-12-31","value":-44100000,"profit":false},{"date":"2022-12-31","value":-49000000,"profit":false},{"date":"2023-12-31","value":-83000000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 38.97M | 33.64M | 52.23M | 61.21M | 35.63M | [{"date":"2019-12-31","value":63.67,"profit":true},{"date":"2020-12-31","value":54.96,"profit":true},{"date":"2021-12-31","value":85.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":58.21,"profit":true}] |
Operating Income | (38.97M) | (33.64M) | (52.23M) | (61.21M) | (39.91M) | [{"date":"2019-12-31","value":-3897100000,"profit":false},{"date":"2020-12-31","value":-3363700000,"profit":false},{"date":"2021-12-31","value":-5222700000,"profit":false},{"date":"2022-12-31","value":-6120700000,"profit":false},{"date":"2023-12-31","value":-3990500000,"profit":false}] |
Total Non-Operating Income/Expense | 2.46M | (1.20M) | 631.00K | 305.00K | 3.19M | [{"date":"2019-12-31","value":77.27,"profit":true},{"date":"2020-12-31","value":-37.63,"profit":false},{"date":"2021-12-31","value":19.79,"profit":true},{"date":"2022-12-31","value":9.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (36.51M) | (34.84M) | (51.75M) | (61.62M) | (38.35M) | [{"date":"2019-12-31","value":-3650700000,"profit":false},{"date":"2020-12-31","value":-3483700000,"profit":false},{"date":"2021-12-31","value":-5175200000,"profit":false},{"date":"2022-12-31","value":-6162400000,"profit":false},{"date":"2023-12-31","value":-3834900000,"profit":false}] |
Income Taxes | 1.91M | 1.20M | (475.00K) | 417.00K | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":62.73,"profit":true},{"date":"2021-12-31","value":-24.83,"profit":false},{"date":"2022-12-31","value":21.8,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (38.42M) | (36.04M) | (51.28M) | (62.04M) | - | [{"date":"2019-12-31","value":-3842000000,"profit":false},{"date":"2020-12-31","value":-3603700000,"profit":false},{"date":"2021-12-31","value":-5127700000,"profit":false},{"date":"2022-12-31","value":-6204100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (36.51M) | (34.84M) | (51.75M) | (61.88M) | (45.94M) | [{"date":"2019-12-31","value":-3650700000,"profit":false},{"date":"2020-12-31","value":-3483700000,"profit":false},{"date":"2021-12-31","value":-5175200000,"profit":false},{"date":"2022-12-31","value":-6188300000,"profit":false},{"date":"2023-12-31","value":-4594300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (38.42M) | (36.04M) | (51.28M) | (62.04M) | (38.35M) | [{"date":"2019-12-31","value":-3842000000,"profit":false},{"date":"2020-12-31","value":-3603700000,"profit":false},{"date":"2021-12-31","value":-5127700000,"profit":false},{"date":"2022-12-31","value":-6204100000,"profit":false},{"date":"2023-12-31","value":-3834900000,"profit":false}] |
EPS (Diluted) | - | (100.38) | (2.05) | (2.43) | (1.46) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-10038,"profit":false},{"date":"2021-12-31","value":-205,"profit":false},{"date":"2022-12-31","value":-243,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GLTO | |
---|---|
Cash Ratio | 8.06 |
Current Ratio | 8.68 |
Quick Ratio | 9.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GLTO | |
---|---|
ROA (LTM) | -34.29% |
ROE (LTM) | -72.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GLTO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GLTO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.35 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.46 |
Galecto Inc (GLTO) share price today is $5.62
Yes, Indians can buy shares of Galecto Inc (GLTO) on Vested. To buy Galecto Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLTO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Galecto Inc (GLTO) via the Vested app. You can start investing in Galecto Inc (GLTO) with a minimum investment of $1.
You can invest in shares of Galecto Inc (GLTO) via Vested in three simple steps:
The 52-week high price of Galecto Inc (GLTO) is $23.5. The 52-week low price of Galecto Inc (GLTO) is $5.3.
The price-to-earnings (P/E) ratio of Galecto Inc (GLTO) is
The price-to-book (P/B) ratio of Galecto Inc (GLTO) is 0.35
The dividend yield of Galecto Inc (GLTO) is 0.00%
The market capitalization of Galecto Inc (GLTO) is $7.45M
The stock symbol (or ticker) of Galecto Inc is GLTO